Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
School of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
AAPS PharmSciTech. 2023 Mar 8;24(3):74. doi: 10.1208/s12249-023-02538-3.
The main development process of periodontitis involves periodontal pathogenic bacteria as the initiating factor causing the onset of destructive inflammation, which in turn stimulates the destruction of periodontal tissue. It is difficult to achieve the eradication of periodontitis due to the complex interaction among antibacterial, anti-inflammatory, and bone restoration. Herein, we propose an antibacterial-anti-inflammatory-bone restoration procedural treatment strategy with minocycline (MIN) for the efficient treatment of periodontitis. In brief, MIN was prepared into PLGA microspheres with tunable release behavior using different species of PLGA, respectively. The optimally selected PLGA microspheres (LA:GA with 50:50, 10 kDa, and carboxyl group) had a drug loading of 16.91%, an in vitro release of approximately 30 days, which also had a particle size of approximately 11.8 µm with a smooth appearance and a rounded morphology. The DSC and XRD results showed that the MIN was completely encapsulated in the microspheres as an amorphous state. Cytotoxicity tests demonstrated the safety and biocompatibility of the microspheres (cell viabilities at a concentration of 1-200 μg/mL were greater than 97%), and in vitro bacterial inhibition tests showed that the selected microspheres could achieve effective bacterial inhibition at the initial stage after administration. The favorable anti-inflammatory (low TNF-α and IL-10 levels) and bone restoration effects (BV/TV: 71.8869%; BMD: 0.9782 g/cm; TB.Th: 0.1366 mm; Tb.N: 6.9318 mm; Tb.Sp: 0.0735 mm) were achieved in a SD rat periodontitis model after administering once a week for four weeks. The MIN-loaded PLGA microspheres were proved to be an efficient and safe treatment for periodontitis by procedural antibacterial, anti-inflammatory, and bone restoration.
牙周炎的主要发展过程涉及牙周致病菌作为引发破坏性炎症的起始因素,进而刺激牙周组织破坏。由于抗菌、抗炎和骨修复之间的复杂相互作用,牙周炎很难被根除。在此,我们提出了一种具有米诺环素(MIN)的抗菌-抗炎-骨修复程序治疗策略,用于有效治疗牙周炎。简而言之,使用不同种类的 PLGA 分别将 MIN 制备成具有可调释放行为的 PLGA 微球。经优化选择的 PLGA 微球(LA:GA 为 50:50,10 kDa,羧基)的载药量为 16.91%,体外释放约 30 天,粒径约为 11.8 µm,外观光滑,形态圆润。DSC 和 XRD 结果表明 MIN 完全以无定形态封装在微球中。细胞毒性试验表明微球的安全性和生物相容性(浓度为 1-200 µg/mL 时细胞活力大于 97%),体外抑菌试验表明所选微球在给药初期即可达到有效抑菌。在每周给药一次,共四周的 SD 大鼠牙周炎模型中,实现了良好的抗炎(低 TNF-α和 IL-10 水平)和骨修复效果(BV/TV:71.8869%;BMD:0.9782 g/cm;TB.Th:0.1366 mm;Tb.N:6.9318 mm;Tb.Sp:0.0735 mm)。载 MIN 的 PLGA 微球通过程序抗菌、抗炎和骨修复被证明是一种有效且安全的牙周炎治疗方法。